Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation

Cardiology

Volumn 114, Issue 3, 2009, Pages 167-173

  Madsen, Lene H ^a,b,d   Lund, Terje ^a,b   Grieg, Zanina ^a,b   Nygaard, Ståle ^b,c   Holmvang, Lene ^d   Jurlander, Birgit ^d   Grande, Peer ^d   Christensen, Geir ^b,c   Atar, Dan ^a,b  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d Mental Health Services CPH   (Denmark)

Author keywords

Hypertrophic obstructive cardiomyopathy; Septal alcohol ablation; Troponin degradation

Indexed keywords

TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MOLECULAR WEIGHT; PERCUTANEOUS BIOPSY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; ST SEGMENT ELEVATION;

EID: 67649421295     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000226596     Document Type: Article

References (11)

1. Dean KJ, Wu AH: Biochemistry and molecular biology of troponin I and T; in Cardiac Markers. Berlin, Springer, 2003, pp 193-204.
2. Katus HA, Remppis A, Scheffold T, Diederich KW, Kuebler W: Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991;67:1360-1367.
3. Hastie TJ: Generalized additive models; in Chambers JM, Hastie TJ (eds): Statistical Models. Pacific Grove, Wadsworth & Brooks/Cole, 1992.
4. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE: Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000;102:1221-1226. (Pubitemid 30728118)
5. McDonough JL, Labugger R, Pickett W, Tse MY, MacKenzie S, Pang SC, Atar D, Ropchan G, Van Eyk JE: Cardiac troponin I is modified in the myocardium of bypass patients. Circulation 2001;103:58-64. (Pubitemid 32050436)
6. Madsen LH, Christensen G, Lund T, Serebruany VL, Granger CB, Hoen I, Grieg Z, Alexander JH, Jaffe AS, Van Eyk JE, Atar D: Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. Circ Res 2006;99:1141-1147. (Pubitemid 44729939)
7. Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997;350:127-133.
8. Sigwart U: Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
9. Seggewiss H, Faber L, Gleichmann U: Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999;47:94-100. (Pubitemid 29210533)
10. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines; European Society of Cardiology: American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-1713.
11. Baggish AL, Smith RN, Palacios I, Vlahakes GJ, Yoerger DM, Picard MH, Lowry PA, Jang lK, Fifer MA: Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 2006;92:1773-1778.